In this interview, Oncology Data Advisor speaks with Dr. Christopher Iannuzzi of Hartford HealthCare about an ongoing clinical trial investigating the personalization of prostate cancer treatment through genomic tumor testing. In addition, Dr. Iannuz...
For this interview in honor of Testicular Cancer Awareness Month, Dr. Sam Kaffenberger, an Assistant Professor of Urology at the University of Michigan Health System, explains the importance of taking a nuanced approach to the management of individua...
For patients with testicular cancer, planning is necessary to ensure that patients feel prepared regarding the implications of their disease in the years after they finish treatment. In this interview in honor of Testicular Cancer Awareness Month, Dr...
Oncology Data Advisor™ · Taking a Nuanced Approach to Testicular Cancer Management With Sam Kaffenberger, MD For this interview in honor of Testicular Cancer Awareness Month, Dr. Sam Kaffenberger, an Assistant Professor of Urology at the...
Oncology Data Advisor™ · Prioritizing Life After Testicular Cancer With Katie Murray, DO For patients with testicular cancer, planning is necessary to ensure that patients feel prepared regarding the implications of their disease in the ...
Oncology Data Advisor™ · Exploring Recent Advances in Testicular Cancer Surgery and Access to Care This interview in honor of Testicular Cancer Awareness Month features Dr. Andrew Winer, Chief of Urology at Kings County Hospital in New Y...
An educational activity provided by i3 Health has produced knowledge gains and expertise regarding the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). In the United States, prostate cancer is the most common tumor type affecti...
The FDA has approved darolutamide (Nubeqa®, Bayer HealthCare Pharmaceuticals Inc.) in combination with docetaxel for adult patients with metastatic hormone-sensitive prostate cancer (mHSPC). "Standard treatment for patients with metastatic, hormone-s...
An educational live and enduring activity provided by i3 Health has demonstrated knowledge gains and learning outcomes for nurses treating patients with castration-resistant prostate cancer (CRPC). Prostate cancer is the most common tumor type in men...

Copyright © 2022 Oncology Data Advisor. All rights reserved.